Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
blinatumomab + venetoclax
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Blinatumomab + venetoclax is an investigational combination therapy for hematologic malignancies, primarily relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and minimal residual disease (MRD)-positive BCP-ALL. Blinatumomab is a bispecific T-cell engager antibody construct that targets CD19 on B cells and CD3 on T cells, redirecting cytotoxic T cells to eliminate malignant B cells. Venetoclax is a small molecule inhibitor of the anti-apoptotic protein BCL-2, promoting apoptosis in cancerous lymphoid cells. The combination aims to enhance anti-leukemic efficacy by leveraging both immune-mediated cytotoxicity and direct induction of apoptosis. Early-phase clinical trials have shown promising activity in patients with high leukemia burden or poor prognosis who are not responsive to standard therapies[1][2][8].
- Other names
- blinatumomab plus venetoclaxvenetoclax plus blinatumomab
02
Targets
BCL-2 (BCL-2 family)CD19 (B lymphocyte antigen CD19)CD3E (T-cell surface glycoprotein CD3 epsilon chain receptor)
Beyond the preview
Go deeper on blinatumomab + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on blinatumomab + venetoclax.